Neuroscience and neurology are dynamic components of the healthcare sector and have assumed great importance to regulators as well as investors due to the rising awareness about various mental diseases. As a result, the research and development pipeline in the neurology sector is a highly fertile one.
Here’s a roundup of the best bits from neurology and neuroscience research in May 2017:
Genetic Basis of Intelligence Identified
Despite knowing that a large part of our intelligence is down to our genes – some estimates claim that as much as 80% of human intelligence is genetic – we know next to nothing about which genes are actually responsible for intelligence. A new study released this month aims to solve this very mystery. Genetic data from 78,000 individuals was collected, and revealed 52 genes closely associated with intelligence. The findings included 40 novel genes that were also associated with other traits such as neurodegenerative diseases and obesity.
Noninvasive Method of Deep Brain Stimulation Developed
Deep brain stimulation has been shown to be an effective treatment in several brain disorders, including major diseases such as Parkinson’s disease and epilepsy as well as relatively minor psychological conditions such as obsessive compulsive disorder and depression. However, the inevitably invasive nature of deep brain stimulation has made the process risky as well as costlier. This makes the development of a new brain stimulation technique vital, as it involves the use of electrodes placed on the scalp rather than inserted into the brain.
Cheaper Treatment of Multiple Sclerosis Discovered
Science is famous for having accidents and sheer creative thinking to thank for so many vital discoveries, and the recent redirection of antibiotic minocycline into the treatment of multiple sclerosis. Antibiotic minocycline isn’t new to the medical industry, but it has traditionally been used only in acne treatment. However, its clear benefits against inflammation have now made it a leading candidate for multiple sclerosis treatment, as phase III trials have shown that antibiotic minocycline hinders the progression of multiple sclerosis, given the treatment is started early enough in the disease’s progression.